sever
acut
respiratori
syndrom
sar
caus
coronaviru
sarscov
potenti
threaten
global
public
health
socioeconom
stabil
evid
antibodydepend
enhanc
ade
sarscov
infect
vitro
nonhuman
primat
cloud
prospect
safe
vaccin
use
antibodi
sar
patient
identifi
character
sarscov
bcell
peptid
epitop
dispar
function
rhesu
macaqu
spike
glycoprotein
peptid
elicit
antibodi
effici
prevent
infect
nonhuman
primat
contrast
peptid
induc
antibodi
enhanc
infect
vitro
nonhuman
primat
use
epitop
sequencedepend
esd
mechan
peptid
exhibit
high
level
serolog
reactiv
result
addit
respons
two
tandem
epitop
longterm
human
bcell
memori
respons
antisera
convalesc
sar
patient
thu
peptidebas
vaccin
sarscov
could
engin
avoid
ade
via
elimin
epitop
provid
herein
altern
strategi
prepar
safe
effect
vaccin
ade
viral
infect
identifi
elimin
epitop
sequencedepend
enhanc
viral
infect
novel
sever
acut
respiratori
syndrom
coronaviru
sarscov
character
march
global
effort
follow
first
epidemiolog
case
novemb
ten
year
later
novel
middl
east
respiratori
syndrom
mer
coronaviru
emerg
similar
sarscov
sar
deadli
infecti
diseas
potenti
serious
threaten
public
health
socioeconom
stabil
worldwid
serolog
genet
investig
indic
sarscov
zoonot
origin
bat
like
anim
reservoir
sinc
identif
sarscov
major
advanc
understand
sarscov
genet
molecular
epidemiolog
identif
host
receptor
tcell
epitop
model
mice
ferret
monkey
establish
particular
strength
weak
vaccin
candid
includ
dna
live
attenu
strain
recombin
protein
inactiv
whole
virion
vector
vaccin
howev
none
approv
clinic
investig
safeti
concern
sarscov
vaccin
rais
given
observ
vitro
antibodydepend
enhanc
ade
sarscov
infect
could
theori
exacerb
diseas
observ
includ
evid
ade
report
first
time
induc
inactiv
sarscov
vaccin
rhesu
macaqu
figur
antisera
sar
patient
tabl
well
ade
coronaviru
infect
ade
vitro
observ
mani
virus
includ
yellow
fever
viru
west
nile
viru
human
immunodefici
viru
hiv
ebola
viru
respiratori
syncyti
viru
rsv
influenza
viru
hivinduc
ade
describ
exact
mechan
still
uncertain
among
exampl
ade
secondari
infect
dengu
viru
heterolog
serotyp
associ
immunopatholog
vascular
leakag
hemorrhag
syndrom
dengu
hemorrhag
feverdengu
shock
syndrom
dhf
dss
descript
ade
relat
fcgamma
receptor
andor
complement
compon
promot
viral
uptak
viru
replic
pathway
goncalvez
et
al
report
treatment
juvenil
rhesu
monkey
crossreact
mab
recogn
fusion
loop
dii
dengu
viru
enhanc
viremia
sever
log
within
day
infect
furthermor
acid
aa
delet
nterminu
ch
domain
fc
region
abrog
enhanc
vitro
vivo
confirm
ade
occur
pathway
class
antibodi
anoth
studi
analyz
stoichiometr
relationship
antibodymedi
neutral
enhanc
west
nile
viru
wnv
infect
cell
express
result
show
antibodi
occup
threshold
virion
neutral
enhanc
viru
infect
strongli
neutral
diiilater
ridgespecif
mab
inhibit
lower
occup
wherea
weakli
neutral
mab
bind
distinct
epitop
requir
much
higher
mab
occup
neutral
mab
occup
fall
threshold
neutral
ade
occur
subsequ
studi
group
show
level
antibodi
occup
promot
ade
vivo
also
modul
bind
restrict
ade
igg
subclassspecif
manner
basi
studi
mani
neutral
antibodi
may
enhanc
infect
vitro
cell
concentr
fall
key
occup
threshold
ab
poorli
neutral
may
strongli
enhanc
wide
rang
howev
antibodi
isotyp
bind
avidli
much
enhanc
effect
may
minim
vivo
studi
suggest
ade
may
mechan
antibodi
enhanc
infect
huang
et
al
demonstr
ade
vitro
antiprm
mab
denv
cell
line
lack
express
eg
babi
hamster
kidney
cell
line
murin
fibroblast
cell
importantli
peptid
region
cpflkqnepedidcw
prm
block
ade
dosedepend
manner
antibodi
appear
dual
specif
bound
dengu
viru
virion
andor
crossreact
protein
cell
surfac
thu
ade
via
complementdepend
mechan
plausibl
denv
yet
poorli
character
vitro
vivo
herein
discov
peptid
viral
sequenc
simultan
elicit
antibodi
dispar
function
protect
enhanc
sarscov
infect
studi
host
vero
cell
vitro
nonhuman
primat
vaccin
lung
macaqu
first
observ
ade
sarscov
infect
lung
immun
inactiv
viru
vaccin
macaqu
monkey
without
immun
inactiv
sarscov
vaccin
infect
nasal
caviti
inocul
live
sarscov
virion
figur
infect
macaqu
show
lung
broaden
interv
visibl
macrophag
infiltr
alveolar
epitheli
hyperplasia
howev
ade
macaqu
vaccin
show
lung
broaden
interv
lung
interv
fractur
larg
amount
macrophag
lymphocyt
infiltr
visibl
fibrin
proteinrich
edema
alveolar
caviti
protect
macaqu
show
lung
slightli
anim
challeng
nasal
caviti
inocul
sarscov
tcid
mlmonkey
sarscov
strain
day
boost
anim
sacrif
day
viral
challeng
lung
tissu
sampl
gener
patholog
observ
patholog
examin
procedur
describ
ref
infect
macaqu
lung
interv
broaden
visibl
macrophag
infiltr
alveolar
epitheli
hyperplasia
ade
macaqu
lung
interv
broaden
lung
interv
fractur
larg
amount
macrophag
lymphocyt
infiltr
visibl
fibrin
proteinrich
edema
alveolar
caviti
protect
macaqu
lung
interv
slightli
broaden
without
visibl
abnorm
arrow
indic
lung
lesion
infect
ade
anim
broaden
interv
without
visibl
abnorm
result
impli
simpl
vaccin
inactiv
whole
sarscov
virion
might
ineffect
protect
viru
infect
identif
highli
immunodomin
bcell
peptid
sarscov
human
map
highli
immunoreact
human
bcell
peptid
employ
sar
patient
antisera
carri
number
research
group
consist
previou
report
jiang
laboratori
report
peptid
membran
protein
peptid
n
protein
highli
reactiv
convalescentphas
test
sera
sar
patient
laboratori
wu
che
collabor
identifi
three
conform
amino
acid
three
linear
amino
acid
epitop
fulllength
n
protein
immunodomin
use
split
mix
combinatori
strategi
synthes
overlap
peptid
librari
span
four
structur
protein
sarscov
strain
includ
envelop
e
membran
nucleocapsid
n
spike
screen
peptid
librari
antisera
convalesc
sar
patient
identifi
domin
peptid
epitop
recogn
antisar
igg
experi
paper
indic
three
peptid
protein
strongli
bound
sarscovspecif
human
igg
respect
sar
patient
tabl
extens
peptid
tabl
character
epitop
nand
ctermini
identifi
new
immunodomin
peptid
recogn
antisera
patient
tabl
peptid
specif
reduc
titer
human
igg
convalesc
sera
sar
patient
react
sarscov
viral
lysat
figur
studi
sequenti
collect
sera
convalesc
sar
patient
whose
sera
obtain
month
onset
infect
strongli
react
peptid
antisera
patient
continu
recogn
month
month
month
onset
sar
figur
impli
peptid
major
immunodomin
peptid
human
elicit
longterm
bcell
memori
respons
natur
infect
sarscov
epitopespecif
antibodi
sarscov
exhibit
enhanc
neutral
function
vitro
studi
function
signific
immunodomin
peptid
glycoprotein
gener
monoclon
antibodi
mab
tabl
immun
mice
ten
strongli
bound
sarscov
virion
figur
among
five
block
sarscov
infect
vero
cell
figur
includ
contrast
two
mab
despit
share
isotyp
constant
region
configur
neutral
antipeptid
antibodi
tabl
markedli
enhanc
sarscov
infect
vero
cell
figur
particularli
strike
given
vero
cell
lack
bestunderstood
mechan
ade
involv
fcmediat
intern
replic
viru
tabl
peptid
recogn
sarsinfect
patient
relev
mous
mab
function
classif
red
blue
greencolor
peptid
repres
epitop
assembl
immunogen
peptid
neu
neutral
ade
indic
abil
individu
mab
block
enhanc
respect
sarscov
infect
vero
cell
reactiv
individu
peptid
antisera
convalesc
sar
patient
male
femal
determin
use
elisa
commerci
avail
elisa
kit
use
confirm
antisera
posit
viral
lysat
antigen
cutoff
valu
titer
serum
averag
duplic
well
vero
cell
infect
reduc
dosedepend
manner
unrel
hbv
peptid
figur
b
wherea
ade
human
antisera
sarscovinfect
patient
also
specif
block
peptid
figur
impli
peptidebas
ade
occur
epidem
period
sar
outbreak
antibodypeptid
bind
elisa
indic
react
wherea
bound
figur
data
suggest
induc
consensu
peptid
wherea
ntermin
peptid
lyqdvnc
immun
antigen
synthes
peptid
lyqdvn
lyqdvnc
lyqdvnct
immunoreact
test
sera
sarsposit
patient
confirm
peptid
immunodomin
one
human
figur
alanin
scan
mutagenesi
peptid
demonstr
critic
amino
acid
residu
interact
figur
tabl
peptid
lie
close
cterminu
sarscov
major
receptor
bind
domain
rbd
specul
may
expos
specif
conform
catalyz
sarscov
attach
andor
membran
fusion
target
cell
neutral
enhanc
sarscov
infect
nonhuman
primat
epitopespecif
antibodi
lowmolecularweight
peptid
behav
like
hapten
rel
low
immunogen
make
immunogen
chemic
ligat
four
copi
peptid
lysin
core
brch
coli
ly
brk
ka
scheme
prepar
multipl
antigen
peptid
system
map
purifi
prepar
hplc
figur
tabl
molecular
weight
confirm
lcmsm
figur
use
synthet
map
vaccin
rhesu
monkey
tabl
follow
control
group
receiv
nacl
four
macaqu
randomli
assign
two
group
day
day
postinfect
sacrific
map
given
six
macaqu
randomli
assign
two
group
day
day
postinfect
sacrific
mixtur
map
map
map
given
six
macaqu
randomli
assign
two
group
day
day
postinfect
sacrific
mixtur
map
map
map
given
six
macaqu
randomli
assign
two
group
day
day
postinfect
sacrific
immun
protocol
includ
one
prime
inject
follow
three
boost
interv
chart
antipeptid
polyclon
ab
monkey
igg
monitor
elisa
show
highlevel
respons
immun
peptid
three
boost
figur
left
antibodi
figur
four
peptid
sera
anim
background
level
blood
collect
day
gradual
induc
anti
peptid
antibodi
three
boost
surprisingli
immun
elicit
high
level
igg
peptid
vaccin
compon
consist
epitop
two
anim
group
anti
antibodi
anim
group
reach
highest
level
second
boost
day
first
inject
averag
titer
anti
igg
greater
monkey
sarscov
challeng
time
respect
interestingli
anim
challeng
sarscov
igg
level
gradual
decreas
figur
day
postinfect
differ
immun
igg
level
inexplic
increas
day
postinfect
subsequ
decreas
day
postinfect
observ
impli
anti
antibodi
strongli
involv
neutral
sarscov
monkey
exist
epitop
may
reduc
total
titer
anti
antibodi
immun
macaqu
subsequ
challeng
sarscov
strain
via
nasal
inhal
day
last
boost
describ
day
postinfect
dpi
macaqu
sacrif
chart
tabl
data
lung
damag
viral
burden
macaqu
summar
tabl
gross
lung
patholog
evid
dpi
group
mockimmun
macaqu
averag
patholog
grade
grade
iv
figur
b
tabl
sever
diffus
alveolar
damag
includ
alveolar
shrink
ruptur
elast
fiber
massiv
macrophag
infiltr
associ
fusion
alveolar
septa
pulmonari
edema
fibrin
hemorrhag
cellular
debri
contribut
sever
interstiti
pneumon
damag
similar
grade
iv
somewhat
reduc
grade
markedli
diminish
grade
immunohistochemistri
use
mab
viral
peptid
reveal
larg
number
sarscovinfect
macrophag
alveolar
epitheli
cell
group
figur
averag
infect
cell
per
highpow
field
hpf
infect
cell
per
hpf
dpi
respect
quantit
viral
burden
analysi
quantit
rtpcr
show
averag
copiesmg
lung
tissu
dpi
copiesmg
lung
tissu
dpi
sarscov
lung
group
compar
group
group
show
similar
histolog
dpi
interstiti
pneumonia
far
wors
dpi
character
massiv
number
inflammatori
cell
hemorrhag
septa
extens
exud
sarscovinfect
cell
lung
averag
per
hpf
dpi
per
hpf
dpi
wherea
viral
copi
lung
tissu
mg
lung
tissu
respect
thu
even
though
immunodomin
patient
antigen
monkey
reactiv
neutral
mab
nonprotect
even
harm
use
vaccin
contrast
immun
monkey
group
strongli
increas
abil
control
sarscov
infect
associ
induct
high
level
anti
antibodi
figur
dpi
hemorrhag
septa
elast
fiber
alveolar
wall
indic
appar
inflamm
silver
stain
result
alveolu
septa
broaden
increas
infiltr
inflammatori
cell
record
dpi
indic
earli
acut
diffus
alveolar
damag
occur
sarscovinfect
lung
cell
group
averag
per
hpf
vs
group
p
per
hpf
vs
group
p
dpi
respect
sarscov
burden
averag
copiesmg
lung
tissu
dpi
copiesmg
lung
tissu
dpi
repres
ratio
number
sarscov
copi
group
dpi
respect
anim
receiv
symptom
acut
diffus
alveolar
damag
visibl
includ
fusion
thick
septa
ruptur
elast
fiber
alveoli
averag
number
sarscov
infect
cell
lung
tissu
per
hpf
dpi
vs
group
p
per
hpf
dpi
vs
group
p
sarscov
burden
cutoff
valu
set
averag
bind
unrel
b
neutral
enhanc
sarscov
infect
vero
cell
mab
specif
reduc
correspond
immunopeptid
hepat
b
viru
hbv
peptid
hbv
peptid
lldyqgmlpv
unrel
control
peptid
hbv
surfac
protein
hbv
peptid
preincub
correspond
mab
human
antisera
min
function
test
experi
perform
triplic
data
present
mean
standard
deviat
averag
copiesmg
lung
tissu
dpi
time
burden
copiesmg
lung
tissu
dpi
group
also
show
increas
group
copiesmg
vs
copiesmg
viral
burden
dpi
suggest
presenc
igg
facilit
sarscov
infect
immun
macaqu
separ
experi
focus
phenomenon
ade
macaqu
rhesu
monkey
divid
six
group
n
per
group
tabl
three
group
separ
sacrif
dpi
time
point
includ
control
group
two
group
receiv
enhanc
dose
mgkg
mgkg
day
prior
challeng
sarscov
strain
gross
patholog
chang
record
control
group
grade
iv
level
figur
b
although
clear
patholog
chang
observ
one
three
monkey
mgkg
group
conclud
previou
treatment
dose
mgkg
averag
significantli
reduc
facilit
sarscov
infect
howev
macaqu
treat
mgkg
show
mark
increas
lung
lesion
lung
lesion
area
macaqu
cm
dpi
largest
dic
experiment
group
dpi
lung
mg
kg
group
show
larger
area
necrosi
sever
sheet
septa
fusion
necrot
lesion
hemorrhag
septa
massiv
macrophag
infiltr
alveoli
indic
interstiti
pneumonia
much
sever
group
control
group
figur
sarscovinfect
cell
lung
tissu
per
hpf
dpi
per
hpf
dpi
p
vs
control
group
averag
sarscov
burden
lung
copiesmg
lung
tissu
dpi
copiesmg
lung
tissu
dpi
enhanc
compar
control
group
dpi
enhanc
dpi
figur
result
confirm
enhanc
sarscov
infect
macaqu
directli
relat
antibodi
studi
report
first
time
sarscov
inactiv
vaccin
could
induc
ade
lung
patholog
experiment
rhesu
monkey
four
antigen
peptid
spike
protein
sarscov
identifi
high
crossreact
larg
number
antisera
convalesc
sar
patient
ten
mab
alanin
scan
mutagenesi
indic
andor
critic
amino
acid
residu
respons
enhanc
may
catalyz
sarscov
attach
andor
membran
fusion
target
cell
expos
specif
conform
spike
protein
locat
viru
rbd
block
sarscov
infect
vero
cell
vitro
probabl
interf
highaffin
attach
sar
virion
human
receptor
residu
rbd
coronaviru
spike
protein
character
class
fusion
protein
contain
highli
conserv
heptad
repeat
region
thu
interf
bind
becom
recent
target
prevent
viral
fusion
entri
target
cell
overlap
aa
sarscov
spike
glycoprotein
mechan
anti
antibodi
reduc
effici
sarscov
fusion
like
associ
expos
fiveturn
conform
via
bind
extend
conform
form
residu
three
antiparallel
helic
obliqu
orient
surround
parallel
trimer
coiledcoil
three
helic
bind
sarscov
virion
strongest
among
mab
figur
impli
peptid
may
act
major
immunoantigen
sever
lung
injuri
occur
one
challeng
rhesu
monkey
immun
inactiv
sarscov
vaccin
figur
strong
serolog
reactiv
antisera
convalesc
sar
patient
observ
respons
two
tandem
epitop
epitop
gener
antibodi
dispar
function
regard
neutral
enhanc
sarscov
infect
thu
person
infect
sarscov
enhanc
antibodi
neutral
antibodi
may
partli
counteract
function
sarscov
ade
also
report
research
laboratori
use
hlcz
human
promonocyt
cell
line
chen
huang
found
higher
concentr
antisera
collect
sarscovinfect
patient
facilit
sarscov
infect
induc
higher
level
virusinduc
apoptosi
demonstr
phenomenon
occur
via
antispik
protein
antibodi
mediat
ade
via
antin
protein
antibodi
bruzzon
jaum
laboratori
show
antispik
immun
serum
increas
infect
human
monocytederiv
macrophag
replicationcompet
sarscov
well
spikepseudotyp
lentivir
particl
sarscovpp
although
clarifi
whether
enhanc
pathway
reaction
bcell
epitop
free
sequenc
contain
cy
residu
prepar
directli
bcell
epitop
without
free
group
anchor
addit
cystein
residu
ctermin
figur
fourbranch
bromin
multipleantigen
core
peptid
brk
ka
figur
via
lysin
two
sidechain
amino
group
prepar
final
conjug
four
copi
individu
antigen
peptid
lentivir
particl
well
replicationcompet
sar
coronaviru
jaum
collabor
propos
ade
sarscov
util
novel
cell
entri
mechan
immun
cell
studi
demonstr
first
time
antibodi
target
specif
linear
epitop
sarscov
spike
protein
mediat
enhanc
viru
infect
vitro
nonhuman
primat
via
epitop
sequencedepend
mechan
also
demonstr
viral
peptid
induc
protect
pathogenesi
identifi
distinguish
induc
enhanc
primat
find
reveal
new
mechan
viru
evas
host
defens
potenti
provid
altern
strategi
prepar
safe
effect
vaccin
ade
viru
infect
peptid
design
synthesi
new
peptid
spike
glycoprotein
design
basi
inform
gain
first
round
immunopeptid
discoveri
peptid
synthes
manual
standard
fmoc
chemistri
protocol
rinkamid
mbha
resin
novabiochem
san
diego
ca
usa
mmolg
amino
acid
coupl
reagent
dic
hobt
obtain
gl
biochem
shanghai
china
solvent
analyt
grade
use
without
purif
amino
acid
assembl
complet
use
equiv
amino
acid
coupl
reagent
ninhydrin
colorimetr
test
coupl
carri
ensur
detect
amino
remain
case
peptidebear
bead
color
posit
ninhydrin
test
free
amino
group
block
react
acet
anhydrid
dichloromethan
dcm
vv
min
crude
peptid
without
cy
met
arg
trp
residu
cleav
use
onestep
tfa
cleavag
method
follow
condit
tfa
ml
deioniz
water
triethyl
silan
peptid
contain
cy
met
arg
trp
residu
follow
condit
use
tfa
ml
thioanisol
ml
phenol
g
deioniz
water
ml
edt
triethylsilan
tfa
solut
treat
icecool
diethyl
ether
precipit
peptid
crude
peptid
wash
twice
icecool
diethyl
ether
dri
n
flow
condit
particular
peptid
synthes
synphas
pa
ram
dseri
lantern
load
mimotop
raleigh
nc
usa
lantern
treat
piperidin
dimethylformamid
dmf
min
deprotect
gener
coupl
condit
lantern
util
solut
dmf
dcm
reagent
follow
concentr
aa
mm
hobt
mm
dic
mm
lantern
minimum
activ
amino
acid
solut
requir
altern
bromophenol
blue
coupl
solut
use
indic
monitor
reaction
simultan
sidechain
deprotect
cleavag
carri
use
ml
per
lantern
solut
trifluoroacet
acid
tfa
h
crude
peptid
purifi
hplc
puriti
semiprepar
rp
column
zorbax
mm
agil
colorado
spring
co
usa
elut
mlmin
ch
cn
buffer
b
gradient
water
buffer
contain
tfa
min
follow
ch
cn
min
pure
peptid
identifi
shimadzu
analyt
hplc
system
column
mm
mm
agil
lcmsd
tof
figur
branch
lysin
core
brch
coli
ly
scaffold
synthes
manual
standard
fmoc
chemistri
protocol
mmol
mg
rinkamid
mbha
resin
novabiochem
mmolg
describ
fmoc
use
branch
point
fmocprotect
amino
acid
equiv
assembl
use
equiv
dic
coupl
reagent
hobt
addit
ntermini
four
branch
lysin
core
bromoacetyl
resin
equiv
bromoacet
acid
dic
dmf
h
bromoacetyl
lysin
core
cleav
resin
treatment
h
tfa
h
precipit
cold
diethyl
ether
lyophil
purifi
hplc
semiprepar
rp
column
zorbax
mm
elut
ml
tabl
averag
igg
level
peptid
vaccin
group
monitor
elisa
day
inject
boost
igg
level
b
averag
group
macaqu
titer
anti
igg
greater
relev
immun
monkey
group
averag
gross
lung
patholog
determin
standard
tabl
b
sarscovinfect
macrophag
alveolar
epitheli
cell
vaccin
group
count
use
antipeptid
antibodi
c
quantit
viral
burden
analysi
quantit
rtpcr
viral
copiesmg
lung
tissu
map
prepar
immun
use
modifi
chemic
ligat
protocol
ligat
achiev
mix
lysin
core
peptid
solvent
certain
ph
valu
reaction
monitor
analyt
rp
column
kromasil
nest
group
inc
southborough
usa
nm
wavelength
appear
complet
reaction
quench
ad
tfa
adjust
ph
final
product
purifi
semiprepar
hplc
flow
rate
mlmin
ligat
peptid
lyophil
character
agil
lcmsd
tof
prepar
condit
map
list
tabl
detail
antisera
sar
patient
sera
healthi
volunt
involv
studi
conduct
accord
guidelin
treatment
human
subject
nation
institut
health
usa
written
inform
consent
obtain
studi
particip
pepscan
carri
describ
hu
et
al
without
major
modif
optic
densiti
read
nm
optic
densiti
reader
labsystem
franklin
usa
cutoff
valu
determin
twice
averag
valu
neg
control
bind
mous
monoclon
antibodi
sarscov
virion
sarscov
strain
dilut
coat
buffer
tcid
ml
bicarbonatecarbon
coat
buffer
ph
viru
coat
plate
tcid
viru
per
well
h
coat
buffer
remov
well
block
buffer
ad
per
well
incub
h
bsa
pb
ph
gibco
carlsbad
ca
usa
plate
wash
twice
pb
ph
mous
monoclon
antibodi
sarscov
control
mab
dilut
block
buffer
ad
well
separ
incub
h
plate
wash
twice
pb
secondari
antibodi
hrpconjug
goat
antimous
igg
genetex
irvin
ca
usa
dilut
block
buffer
ad
well
incub
h
secondari
antibodi
remov
plate
wash
three
time
pb
tmb
substrat
solut
promega
madison
wi
usa
ad
well
incub
min
room
temperatur
absorb
test
well
read
nm
analysi
neutral
use
neutral
red
stain
nr
base
assay
mab
serial
dilut
dmem
cultur
medium
human
polyclon
antisera
convalesc
sar
patient
dilut
vv
sarscov
strain
dilut
dmem
tcid
nr
neutral
assay
perform
flatbottom
plate
setup
similar
cytopath
effect
cpe
base
neutral
assay
incub
tcid
viru
antibodi
antisera
total
dmem
medium
per
well
h
vero
cell
cell
cell
cultur
center
pumc
ad
well
day
infect
cell
show
cpe
viral
control
well
dmem
instead
antibodi
antisera
cultur
medium
remov
test
well
neutral
red
sigma
st
loui
mo
usa
dmem
ad
well
incub
h
neutral
red
medium
remov
plate
wash
twice
pb
ph
acidifi
alcohol
acet
acid
ethanol
ad
well
incub
min
room
temperatur
absorb
neutral
red
stain
plate
read
nm
percent
neutral
determin
follow
formula
neutral
antibodi
test
well
viral
control
well
cell
control
well
viral
control
well
gener
purif
measur
affin
antipeptid
monoclon
antibodi
ganptransgen
mice
origin
establish
strain
describ
previous
mice
backcross
balbc
mice
least
eight
gener
use
immun
establish
mab
mice
maintain
specif
pathogenfre
condit
center
anim
resourc
develop
card
kumamoto
univers
immunogen
four
peptid
synthes
conjug
keyhol
limpet
hemocyanin
klh
operon
biotechnolog
tokyo
japan
one
hundr
microgram
emulsifi
complet
freund
adjuv
cfa
inject
subcutan
primari
immun
boost
week
incomplet
freund
adjuv
ifa
sera
immun
mice
measur
elisa
use
plate
coat
free
peptid
mice
highest
serum
ab
titer
immun
day
later
spleen
cell
obtain
polyethylen
glycolmedi
cell
fusion
mous
myeloma
cell
line
use
standard
procedur
fuse
cell
select
hat
medium
microcultur
plate
concentr
cellswel
presenc
unitsml
mab
bind
immun
peptid
ag
detect
hrpconjug
goat
antimous
igg
ab
zyme
south
san
francisco
ca
usa
substrat
opd
wako
chemic
osaka
japan
posit
signal
select
hybridoma
clone
limit
dilut
method
adapt
serumfre
media
purifi
protein
gsepharos
affin
chromatographi
ge
healthcar
buckinghamshir
uk
puriti
antibodi
examin
sdspage
protein
stain
coomassi
brilliant
blue
heavi
light
chain
isotyp
determin
use
isotyp
kit
bd
bioscienc
franklin
lake
nj
usa
affin
mab
peptid
determin
biacor
assay
onand
offrat
constant
k
k
bind
mab
peptid
tabl
determin
use
biacor
system
biacor
intern
ab
uppsala
sweden
carboxylmethyl
dextran
surfac
sensor
chip
activ
carbodiimid
nhydroxysuccinimid
peptid
immobil
free
thiol
group
cystein
residu
deliber
place
nterminu
inject
solut
mm
nmorpholino
ethanesulfon
acid
buffer
ph
surfac
react
ethaneamin
excess
disulfid
group
deactiv
addit
cystein
mab
dilut
mm
hepe
ph
mm
nacl
mm
edta
vv
biacor
surfact
inject
immobil
antigen
flow
rate
associ
monitor
increas
refract
index
sensor
chip
surfac
per
unit
time
dissoci
mab
monitor
end
associ
phase
flow
rate
kinet
rate
constant
calcul
collect
data
use
pharmacia
kinet
evalu
softwar
k
determin
measur
rate
bind
antigen
differ
protein
concentr
macaqu
experi
challeng
sarscov
monkey
challeng
perform
facil
briefli
anim
anesthet
ketamin
mlkg
im
tcid
mlmonkey
stock
strain
viru
spray
nasal
caviti
anim
patholog
examin
lung
tissu
sampl
euthan
anim
organ
examin
grossli
photograph
taken
record
lung
damag
sampl
g
lung
tissu
collect
lung
frozen
remain
tissu
fix
formaldehyd
week
laboratori
tissu
process
regular
patholog
laboratori
dehydr
embed
section
hematoxylin
eosin
h
e
stain
section
sequenti
treat
xylen
min
xylen
ii
min
alcohol
min
alcohol
min
alcohol
min
alcohol
min
alcohol
min
pb
min
section
stain
hematoxylin
min
wash
tap
water
doubledistil
water
pb
min
alcohol
eosin
alcohol
alcohol
alcohol
ii
xylen
min
xylen
ii
min
xylen
iii
min
mount
mount
buffer
zhongshan
inc
guangzhou
china
immunohistochem
analysi
infect
lung
tissu
mixtur
mous
monoclon
antibodi
use
primari
antibodi
immunohistochem
analysi
infect
lung
tissu
briefli
tissu
section
treat
primari
antibodi
overnight
wash
three
time
pb
incub
igg
zhongshan
inc
prc
min
wash
three
time
pb
dab
substrat
ad
incub
min
stain
hematoxylin
min
rtpcr
analysi
sarscov
burden
tissu
cranial
caudal
lobe
left
lung
cranial
middl
caudal
lobe
right
lung
anim
sampl
pool
togeth
total
rna
isol
lung
tissu
use
trizol
invitrogen
usa
one
hundr
milligram
lung
tissu
mix
ml
trizol
extract
buffer
homogen
homogen
ika
germani
rna
wan
extract
chloroform
precipit
isopropanol
rna
dissolv
depc
water
rna
qualiti
verifi
electrophoresi
agaros
gel
revers
transcript
total
rna
revers
transcrib
highcapac
cdna
kit
recertaid
first
strand
cdna
synthesi
kit
fermenta
glen
burni
md
usa
random
hexam
primer
reaction
perform
min
termin
min
two
microlit
revers
transcript
mixtur
use
templat
primer
sarscov
pcr
normal
monkey
glyceraldehyd
phosphat
dehydrogenas
gapdh
gapdh
primer
product
size
bp
pcr
perform
pcr
kit
taq
dna
polymeras
fermenta
pcr
product
detect
agaros
gel
electrophoresi
reaction
condit
follow
taq
buffer
mm
dntp
forward
primer
revers
primer
taq
dna
polymeras
mm
mgcl
templat
dna
cdna
h
step
min
step
cycl
min
qrtpcr
analysi
sarscov
burden
sarscov
fragment
prepar
rtpcr
bp
fragment
sarscov
amplifi
separ
agaros
electrophoresi
dna
fragment
recov
gel
gel
extract
kit
minelut
gel
extract
kit
qiagen
stanford
valencia
ca
usa
recov
dna
measur
adjust
concentr
use
gener
standard
curv
known
copi
number
standard
curv
use
calcul
copi
number
sarscov
mrna
infect
lung
tissu
rtpcr
infect
sampl
perform
condit
use
standard
curv
roch
light
cycler
follow
instruct
sybr
green
realtim
pcr
master
mix
toyobo
osaka
japan
copi
number
viru
detect
follow
briefli
revers
transcript
mixtur
step
use
templat
primer
sarscov
reaction
continu
cycl
condit
quantitect
sybr
green
pcr
gorward
primer
tevers
primer
rnasefre
water
yemplat
dna
cdna
total
volum
step
min
step
cycl
move
melt
curv
procedur
immun
monkey
peptid
andor
peptid
mixtur
dissolv
peptid
nacl
formul
equal
volum
freund
complet
adjuv
fca
sigma
st
loui
mo
usa
accord
manufactur
instruct
inject
dose
vaccin
kgmonkey
kgmonkey
given
intramuscular
im
inject
four
site
arm
leg
rhesu
monkey
boost
week
first
inject
dose
peptid
volum
vaccin
first
inject
formul
equal
volum
freund
incomplet
adjuv
ifa
sigma
venou
blood
sampl
mleach
collect
everi
day
monkey
sera
isol
centrifug
rpm
immedi
store
antipeptid
igg
detect
elisa
free
peptid
dilut
carbon
buffer
ph
final
concentr
one
hundr
microlit
peptid
solut
ad
polystyren
high
bind
micropl
corn
life
scienc
santa
clara
ca
usa
coat
overnight
well
plate
wash
three
time
pbstween
buffer
mm
phosphat
buffer
mm
nacl
tween
ph
subsequ
block
bsa
pbstween
buffer
addit
h
three
thorough
wash
well
pbstween
buffer
antigenco
micropl
incub
dilut
monkey
sera
room
temperatur
h
three
wash
pbstween
buffer
bound
antibodi
detect
hrpconjug
goat
antimonkey
igg
vv
gene
tex
three
wash
pbstween
tmb
substrat
solut
promega
madison
wi
usa
ad
color
develop
min
reaction
stop
h
absorb
nm
read
use
microtit
plate
reader
macaqu
treat
eighteen
rhesu
monkey
six
group
tabl
year
old
examin
accord
nation
microbiolog
parasit
spf
standard
verifi
free
antisar
antibodi
adjust
concentr
mgml
nacl
respect
dose
mgkg
antibodi
given
intraven
iv
inject
use
treat
differ
group
volum
nacl
use
control
group
procedur
approv
anim
use
care
committe
institut
laboratori
anim
scienc
peke
union
medic
colleg
anim
welfar
assur
iacuc
approv
date
septemb
statist
analysi
data
analyz
use
prism
softwar
graphpad
softwar
neutral
assay
elisa
mean
standard
deviat
use
determin
signific
qrtpcr
geometr
mean
standard
deviat
use
determin
viru
burden
